Livagen vs Thymosin Beta-4
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
LivagenRecovery & RepairAnti-Aging & Longevity
Thymosin Beta-4- Summary
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Half-Life
- Short (minutes); gene-regulatory effects are sustained
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Admin Route
- SubQ, Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 5–10 mg
- Frequency
- Daily for 10–30 days
- 2x per week (loading), then 1x per week (maintenance)
- Key Benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- Stacks With
- —
- —